Occupati Pensionati Casalinghe 0 20 40 60 80 Sì No
88 %
12 %
15 %
85 %
15 %
85 %
n ° P a z ie n ti128
CAPITOLO 10
10.1 Conclusioni
In conclusione, volendo sintetizzare i risultati relativi all’aderenza terapeutica, ottenuti in questo progetto di Pharmaceutical Care svolto in collaborazione fra il Dipartimento di Farmacia dell’Università di Pisa e l’Ordine dei Farmacisti di Massa Carrara, potremmo concludere che il campione analizzato si è mostrato mediamente più aderente rispetto al rapporto presentato dall’AIFA ne “L’uso dei Farmaci in Italia - Rapporto Osmed 2019”. Potremmo comunque delineare i profili/identikit del paziente aderente e del paziente non-aderente, riscontrando una particolarità dei pazienti diabetici di tipo II residenti nella provincia di Massa Carrara rispetto a quelli delle altre province dell’area vasta precedentemente descritte nei progetti portati avanti con l’Ordine di Pisa, Lucca e Livorno (Martelli e Calderone, 2018). Infatti, mentre nei progetti svolti in collaborazione con gli altri Ordini era stato riscontrato un profilo comune di paziente aderente rappresentato da un individuo maschio, <65 anni, sovrappeso, laureato e occupato lavorativamente, nel progetto svolto con l’Ordine dei Farmacisti di Massa Carrara possiamo delineare il profilo del paziente aderente come:
PROFILO/IDENTIKIT DELL’ADERENTE: Femmina >65 anni Obesa Licenza elementare Casalinga
E di quello non aderente come:
PROFILO/IDENTIKIT DEL NON ADERENTE: Maschio
<65 anni Sovrappeso
Licenza media/diploma superiore Occupato/pensionato
129 Grazie a questo progetto siamo stati in grado di elaborare un identikit/profilo che per la provincia di Massa Carrara si è rivelato quasi specularmente opposto rispetto alle altre province dell’area vasta Toscana Nord Ovest dimostrando quindi quanto sia importante fornire ai farmacisti che operano in questa provincia il profilo del paziente sul quale concentrare i propri sforzi educazionali e di “Pharmaceutical Care”. Infatti, come rilevato dai dati ottenuti, le differenze geografiche, antropologiche e culturali influiscono anche sull’aderenza terapeutica. Da ciò si evince quanto sia importante fornire ai farmacisti informazioni che gli consentano di svolgere in maniera accurata, rispetto al territorio nel quale operano, l’atto professionale della presa in carico del paziente cronico e la messa in atto di strategie quali azioni di rinforzo, monitoraggio e spiegazioni calibrate. In questo modo l’azione del farmacista porterà ad un ulteriore incremento dell’aderenza terapeutica soprattutto nei pazienti delineatisi come meno aderenti, e influirà in maniera positiva sia sugli outcomes clinici che sull’impatto economico del SSN.
130
BIBLIOGRAFIA
Abbo ED, Zhang Q, Zelder M, Huang ES. The increasing number of clinical items addressed during the time of adult primary care visits. J Gen Intern Med. 2008;23(12):2058-2065.
Abbott RD, Brand FN, Kannel WB. Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study. Am J Med. 1990;88:376 –381
AIHW. Health and welfare expenditure series no.57. Cat. no. HWE 67. Canberra: AIHW. 2016.
Ali MK, Hindi AMK, Schafheutle EI, Jacobs S. Patient and public perspectives of community pharmacies in the United Kingdom: A systematic review. Res. Soc. Adm. Pharm. 2018;21:409–428.
Al-Lawati JA. Diabetes mellitus: a local and global public health emergency! Oman Med J. 2017;32(3):177–9.
Allemann SS, van Mil JW, Botermann L, Berger K, Griese N, Hersberger KE. Pharmaceutical care: the PCNE definition 2013. Int J Clin Pharm. 2014;36(3):544-555.
Allemann SS, van Mil JWF, Botermann L, Berger K, Griese N, Hersberger KE. Pharmaceutical Care: the PCNE definition 2013. Int J Clin Pharm. 2014;36(3): 544–55.
Al-Quteimat OM, Amer AM. Evidence-based pharmaceutical care: The next chapter in pharmacy practice. Saudi Pharm J. 2016;24(4):447-451.
Alsairafi Z, Waheedi M, Alsaleh F. The perspectives of patients and physicians on the role of pharmacists in improving medication adherence in type 2 diabetes: a qualitative study. Patient Prefer Adherence. 2019;13:1527-1543.
American College of Clinical Pharmacy, Hume AL, Kirwin J, et al. Improving care transitions: current practice and future opportunities for pharmacists. Pharmacotherapy. 2012;32(11):e326-37.
American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 2013;36:1033–46.
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38(Suppl 1):S1-93.
American Diabetes Association. Standards of medical care in diabetes care. Diabetes Care. 2017;40:S1–42.
American Pharmacists Association. National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341–53.
131 American Pharmacists Association. APhA AP. Medication compliance- adherence-persistence (CAP) Digest. Washington DC: American Pharmacists Association and Pfizer Pharmaceuticals. 2003.
Anaya J, Rivera J, Lawson K, Garcia J, Luna J, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaboration drug therapy agreement. Am J Health Syst Pharm. 2008;65(19):1841– 1845.
Anonymous. Editor's Choice. Compliance ± a broken concept. British Medical Journal. 1997;314(7082):1.
Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326–331. Armor B, Britton M, Dennis V, Letassy N. A review of pharmacist contributions to diabetes care in the United States. Int J Pharm Pract. 2010;23(3):250–64. Artinian L. Patients' lack of knowledge of their medications and diagnosis at discharge. Mayo Clin Proc. 2006;81:133.
ASHP. American Society of Health-System Pharmacists. Guidelines on pharmacist-conducted patient education and counselling. Am J Health-Syst Pharm. 1997;54:431–434.
Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response metaanalysis. Eur J Epidemiol. 2015;30:529–42.
Babar ZU, Kousar R, Murtaza G, Azhar S, Khan SA, Curley L. Randomized controlled trials covering pharmaceutical care and medicines management: A systematic review of literature. Res Social Adm Pharm. 2018;14(6):521-539. Baker DW, Parker RM, Williams MV, Clark WS. Health literacy and the risk of hospital admission. J Gen Intern Med. 1998;13(12):791-798.
Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–44. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713- 719.
Barner JC, Bennett RW. Pharmaceutical care certificate program: assessment of pharmacists’ implementation into practice. J Am Pharm Assoc. 1998;39(3):362- 367.
Barnes JM, Riedlinger JE, McCloskey WW, Montagne M. Barriers to compliance with OBRA’90 regulations in community pharmacies. Ann Pharmacother. 1996;30(10):1101-1105.
132 Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34(31):2444-52.
Bergman JF. Self-medication: From European regulatory directives to therapeutic strategy. Fundam Clin. Pharmacol. 2003;17:275–280.
Blackburn DF, Swidrovich J, Lemstra M. Non-adherence in type 2 diabetes: practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;7:183-189.
Borgsteede SD, Karapinar-Carkit F, Hoffmann E, Zoer J, van den Bemt PM. Information needs about medication according to patients discharged from a general hospital. Patient Educ Counsel. 2011;83:22–28.
Borgsteede SD, Westerman MJ, Kok IL, Meeuse JC, de Vries TP, Hugtenburg JG. Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. Int J Clin Pharm. 2011;33(5):779-87.
Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH, Whalley Buono E, Weiss K, Granger CB. Medication adherence: a call for action. Am Heart J. 2011;162(3):412-24.
Bouvy ML. In search of patients for pharmaceutical care. Int J Pharm Pract. 2013;21(4):205–206.
Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc. 2011;86(4):304-314.
Brunner R, Dunbar-Jacob J, Leboff MS, et al. Predictors of adherence in the Women’s Health Initiative Calcium and Vitamin D Trial. Behav Med. 2009;34(4):145-155.
Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12. Bulajeva A, Labberton L, Leikola S, et al. Medication review practices in European countries. Res Social Adm Pharm. 2014;10(5):731–740.
Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77:201–10.
Catic T, Jusufovic FI, Tabakovic V. Patients perception of community pharmacist in bosnia and herzegovina. Mater Sociomed. 2013;25(3):206-9.
CDC. Centers for Disease Control and Prevention. Diabetes-related amputations of lower extremities in the Medicare population--Minnesota, 1993-1995. MMWR Morb Mortal Wkly Rep. 1998;47(31):649-52.
133 Charpentier G, Genes N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab. 2003;29(2 Pt 1):152-58.
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085): 2239–51.
Cheah LP, Amott DH, Pollard J, Watters DA. Electronic medical handover: towards safer medical care. Med J Aust. 2005;183(7):369-72.
Chen H, Ung COL, Chi P, Wu J, Tang D, Hu H. Consumers' Perceptions About Pharmaceutical Care Provided by Community Pharmacists in China in Relation to Over-the-Counter Drugs: A Qualitative Study. Inquiry. 2018;55.
Chinthammit C, Armstrong EP, Boesen K, Martin R, Taylor AM, Warholak T. Cost-effectiveness of comprehensive medication reviews versus noncomprehensive medication review interventions and subsequent successful medication changes in a Medicare Part D population. J Manag Care Spec Pharm. 2015;21:381–9.
Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care 2010;48:923–33.
Cipolle R, Strand L, Morley P. Levels of pharmaceutical care: a needs-basic approach. Am J Hosp Pharm. 1991;48:547–50
Clare J, Hofmeyer A. Discharge planning and continuity of care for aged people: indicators of satisfaction and implications for practice. Aust J Adv Nurs 1998; 16:7–13.
Cohen SG, Bailey DE. What makes teams work: group effectiveness research from the shop floor to the executive suite. J Manag. 1997;23:239–290.
Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011;34(1):77-83.
Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: prevalence and contributing factors. Arch Intern Med. 2005;165(16):1842-7. Colin X, Lafuma A, Gueron B. Costs of cardiovascular events of diabetic patients in the French hospitals. Diabetes Metab. 2007;33:310–3.
Cooper RJ, Tsoneva J. Benefits and tensions in delivering public health in community pharmacies—A qualitative study of healthy living pharmacy staff champions. Int. J. Pharm Pract. 2017;25:351–357.
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
134 Crews JE, Campbell VA. Vision impairment and hearing loss among community- dwelling older Americans: implications for health and functioning. Am J Public Health. 2004;94:823–9.
Cutler RL, Fernandez-Llimos F, Frommer C, Benrimoj M, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8.
De Bolle L, Mehuys E, Christiaens T, Inge Van Tongelen I, Remon JP, Boussery K. Characterisation of patient encounters in community pharmacies (with special focus on self-medication). Int. J. Pharm Pract. 2015; 23:228–231.
de Oliveira DR, Shoemaker SJ. Achieving patient centeredness in pharmacy practice: openness and the pharmacist’s natural attitude. J Am Pharm Assoc JAPhA. 2006;46:56–64.
de Oliveira DR. Atenção Farmacêutica: da Filosofia ao Gerenciamento da Terapia Medicamentosa. São Paulo: RCN Editora. 2011.
De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2008;65:1161–72.
Debussche X. Is adherence a relevant issue in the self-management education of diabetes? A mixed narrative review. Diabetes Metab Syndr Obes. 2014;7:357-67. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. 2006.
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
Department of Health. Pharmacy in England: Building on StrengthsDelivering the Future. 2008.
Diabetes-related amputations of lower extremities in the Medicare population– Minnesota, 1993–1995. MMWR Morb Mortal Wkly Rep. 1998;47:649 – 652. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209. Ding C, Chan Z, Magkos F. Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype. Curr Opin Clin Nutr Metab Care. 2016;19:408–17. DiPietro L, Gribok A, Stevens MS, Hamm LF, Rumpler W. Three 15-min bouts of moderate postmeal walking significantly improves 24-h glycemic control in older people at risk for impaired glucose tolerance. Diabetes Care. 2013; 36:3262–8.
Donovan JL. Patient decision making. The missing ingredient in compliance research. International Journal of Technology Assessment in Health Care. 1995;11:443-455.
135 Droege M. The role of reflective practice in pharmacy. Educ Health. 2003;16(1):68–74.
Dudas V, Bookwalter T, Kerr KM, Pantilat SZ. The impact of follow-up telephone calls to patients after hospitalization. Am J Med. 2001;111(9B):26S- 30S.
Duerden M, Avery T, Payne R. Polypharmacy and Medicines Optimisation. Making It Safe and Sound. London: The King’s Fun. 2013.
Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: A systematic review of pharmacist and consumer views. BMC Public Health. 2011; 11:582.
Einarson TR, Acs A, Ludwig C, Panton UH. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. Value Health. 2018;21(7):881- 890.
Ekenga V, Bailey-Wheeler J, Sarpong D, Hart T, Earls M. Patients’ perception of community pharmacists as healthcare providers and willingness to participate in pharmacist services: A pilot study. J. Pharm. Health Serv. Res. 2018;9:297– 300.
Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S; Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med. 2005;22(10):1420-26.
Ellitt GR, Brien JA, Aslani P, Chen TF. Quality patient care and pharmacists' role in its continuity–a systematic review. Ann Pharmacother. 2009;43:677–691. Ensing HT, Koster ES, Dubero DJ, van Dooren AA, Bouvy ML. Collaboration between hospital and community pharmacists to address drug-related problems: The HomeCoMe-program. Res Social Adm Pharm. 2019;15(3):267-278.
Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of- illness model. J Am Pharm Assoc (Wash). 2001;41:192–9.
Etemad LR, Hay JW. Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program. Value Health. 2003;6:425–435.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486 –2497.
Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucoselowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016;39(2):258-263.
136 Farris KLF, Benrimoj SI. Pharmaceutical care in community pharmacies: practice and research from around the world. Ann Pharmacother. 2005;39(9):1539–41. Fegadolli C, Alvarenga R, Ii R, Benedita C, Iii S, Alegre P, et al. Qualidade de vida como indicador de resultado em Atenção Farmacêutica: enfoque nos conceitos de validação de instrumentos psicométricos Quality of life as an outcome indicator in pharmaceutical care: focus on concepts for the validation of psychometric instruments. Res Gate. 2011;91:133.
Foekema H, Hendrix C. Mistakes Are Expensive, An Investigation Into Medical Transcription Errors, (Part 2). In Fouten Worden Duur Betaald, Een Onderzoek Naar Medische Overdrachtsfouten (Deel 2). Amsterdam: TNS NIPO. 2004. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care. 1999;22:1077–1083.
Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138:161–167.
Fox D, Ried LD, Klein GE, Myers W, Foli K. A medication therapy management program’s impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes. J Am Pharm Assoc (2003). 2009;49(2):192-199.
Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24(10):1105-1113
Friedman B, Basu J. The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev. 2004;61:225–240.
Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36(6):1101–14.
Galozy A, Nowaczyk S, Sant'Anna A, Ohlsson M, Lingman M. Pitfalls of medication adherence approximation through EHR and pharmacy records: Definitions, data and computation. Int J Med Inform. 2020;136:104092.
Gamaleri FC. Community Pharmacy supports and protects public health. Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione. 2016;8(3):11-20.
Gammie T, Vogler S, Babar ZUD. Economic evaluation of hospital and community pharmacy services: a review of the literature (2010-2015). Ann Pharmacother. 2016.
Garattini L, Curto A, Padula A. Reimbursable drug classes and ceilings in Italy: why not only one? Eur J Health Econ. 2016;17(8):923–926.
137 Garattini L, Curto A, Padula A. The puzzle of drug delivery in Italy: who wins? Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):331–332.
Garattini L, Padula A. ‘Appropriateness’ in Italy: a ‘magic word’ in pharmaceuticals? Appl Health Econ Health Policy. 2017;15(1):1–3.
Garattini L, Padula A. Pharmaceutical care in Italy and other European countries: between care and commerce?. Postgrad Med. 2018;130(1):52-54.
Garattini L, van de Vooren K, Curto A. Will the reform of community pharmacies in Italy be of benefit to patients or the Italian National Health Service? Drugs Ther Perspect. 2012;28(11):23–26
Garin N, Koyanagi A, Chatterji S et al. Global multimorbidity patterns: a cross- sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2015;71:205–14.
Gastelurrutia MA, Benrimoj SIC, Castrillon CC. Facilitators for practice change in Spanish community pharmacy. Pharm World Sci. 2009;31(1):32-39.
George PP, Molina JA, Cheah J, et al. The evolving role of the community pharmacist in chronic disease management - a literature review. Ann Acad Med Singapore. 2010;39:861–7.
Gidman W, Ward P, McGregor L. Understanding public trust in services provided by community pharmacists relative to those provided by general practitioners: A qualitative study. BMJ Open. 2012;2.
Goeree R, Morgan E, Lim MA, et al. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can. J Diabetes. 2009;33:35–45.
Golubic R, Wijndaele K, Sharp SJ, Simmons RK, Griffin SJ, Wareham NJ, et al. Physical activity, sedentary time and gain in overall and central body fat: 7-year follow-up of the ProActive trial cohort. Int J Obes (Lond). 2015;39:142–8.
Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients’ perspectives on medication-related problems. Patient Educ Couns. 2007;65(3):407-415.
Goruntla N, Mallela V, Nayakanti D. Impact of Pharmacist-directed Counseling and Message Reminder Services on Medication Adherence and Clinical Outcomes in Type 2 Diabetes Mellitus. J Pharm Bioallied Sci. 2019 Jan- Mar;11(1):69-76.
Guo X, Yao D, Liu J, Huang Y, Wang Y, Yao W. The current status of pharmaceutical care provision in tertiary hospitals: results of a cross-sectional survey in China. BMC Health Serv Res. 2020;20(1):518.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229 –234.
138 Halasyamani L, Kripalani S, Coleman E, Schnipper J, van Walraven C, Nagamine J, Torcson P, Bookwalter T, Budnitz T, Manning D. Transition of care for hospitalized elderly patients – development of a discharge checklist for hospitalists. J Hosp Med. 2006;1:354–360.
Hamilton MT, Hamilton DG, Zderic TW. Sedentary behavior as a mediator of type 2 diabetes. Med Sport Sci. 2014;60:11–26.
Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke. 1998;29:2491–2500.
Hasan S. Teach communication skills to pharmacy students. Am J Parm Educ. 2008;72(3):67.
Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2014;77(1):102–115.
Hawkins SF, Nickman NA, Morse JM. The paradox of safety in medication management. Qual Health Res. 2017;27:1910–23.
Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880-2883.
Hellesø R, Lorensen M, Sorensen L. Challenging the information gap–the patients transfer from hospital to home health care. Int J Med Inform. 2004;73:569–580. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–43.
Herlitz J, Karlson BW, Lindqvist J, et al. Rate and mode of death during five years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. Diabet Med. 1998;15:308–314.
Hersberger KE, Messerli M. Development of clinical pharmacy in Switzerland: involvement of community pharmacists in care for older patients. Drugs Aging. 2016;33(3):205–211.
Hesselink G, Zegers M, Vernooij-Dassen M, et al. Improving patient discharge and reducing hospital readmissions by using Intervention Mapping. BMC Health Serv Res. 2014;14:389.
Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–62.
Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472–1479.
139 Hohl CM, Partovi N, Ghement I, Wickham ME, McGrail K, Reddekopp LN, Sobolev B. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS ONE. 2017;2.
Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65:303–16.
Hoti K, Hughes J, Sunderland B. Pharmacy clients’ attitudes to expanded pharmacist prescribing and the role of agency theory on involved stakeholders. Int. J. Pharm Pract. 2011;19(1):5–12.
Hritcko PM. A new paradigm for pharmacy practice and education. Harvard health policy review. 2006;7(1):143–146.
Hughes CM. Monitoring self-medication. Expert Opin Drug Saf. 2003;2(1):1-5.